3   WHO Drug Information, Vol. 17, No. 2, 2003                                                  Recommended INN: List 49




    International Nonproprietary Names for
    Pharmaceutical Substances (INN)

    RECOMMENDED International Nonproprietary Names
    (Rec. INN): List 49
    Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
    International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
    EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International
    Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not
    imply any recommendation of the use of the substance in medicine or pharmacy.
    Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in Cumulative
    List No. 10, 2002 (available in CD-ROM only).


    Dénominations communes internationales
    des Substances pharmaceutiques (DCI)
    Dénominations communes internationales RECOMMANDÉES
    (DCI Rec): Liste 49
    Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations
    communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60,
    3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par l’Organisation
    mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination
    dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance
    correspondante en médecine ou en pharmacie.
    On trouvera d’autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45)
    dans la Liste récapitulative No. 10, 2002 (disponible sur CD-ROM seulement).


    Denominaciones Comunes Internacionales
    para las Sustancias Farmacéuticas (DCI)
    Denominaciones Comunes Internacionales RECOMENDADAS
    (DCI Rec.): Lista 49
    De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
    Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
    EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a
    continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La
    inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación
    alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
    Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran
    reunidas en Cumulative List No. 10, 2002 (disponible sólo en CD-ROM).


                                                                                                                           115
Recommended INN: List 49                                                        WHO Drug Information, Vol. 17, No. 2, 2003




Latin, English, French, Spanish:
Recommended INN         Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée       Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada       Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada


albaconazolum
albaconazole                         7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-
                                     3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one

albaconazole                         7-chloro-3-[(1R,2R)-2-(2,4-difluorophényl)-2-hydroxy-1-méthyl-
                                     3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one

albaconazol                          7-cloro-3-[(1R,2R)-2-(2,4-difluorofenil)-2-hidroxi-1-metil-
                                     3-(1H-1,2,4-triazol-1-il)propil]quinazolin-4(3H)-ona

                                     C20H16ClF2N5O2
                                                                        F


                                    Cl             N       F
                                                           HO
                                                       N

                                                   O   H CH3 N
                                                                        N
                                                                N


alvimopanum
alvimopan                            [[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl]-
                                     3-phenylpropanoyl]amino]acetic acid

alvimopan                            acide [[(2S)-2-[[(3R,4R)-4-(3-hydroxyphényl)-3,4-diméthylpipéridin-
                                     1-yl]méthyl]-3-phénylpropanoyl]amino]acétique

alvimopán                            ácido [[(2S)-3-fenil-2-[[(3R,4R)-4-(3-hidroxifenil)-3,4-dimetilpiperidin-
                                     1-il]metil]propanoil]amino]acético

                                     C25H32N2O4
                                                                    O

                                                           N                N   CO2H
                                                                    H       H

                                             H3C
                                                   H CH3
                                    HO




116
3   WHO Drug Information, Vol. 17, No. 2, 2003                                               Recommended INN: List 49




    apaziquonum
    apaziquone                           5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(1E)-3-hydroxyprop-1-enyl]-
                                         1-methyl-1H-indole-4,7-dione

    apaziquone                           5-(aziridin-1-yl)-3-(hydroxyméthyl)-2-[(1E)-3-hydroxyprop-1-ényl]-
                                         1-méthyl-1H-indole-4,7-dione

    apazicuona                           5-(aziridin-1-il)-3-(hidroximetil)-2-[(1E)-3-hidroxiprop-1-enil]-1-metil-
                                         1H-indol-4,7-diona

                                         C15H16N2O4

                                                  O       CH3        OH
                                                         N


                                             N
                                                  O          OH




    apolizumabum
    apolizumab                           immunoglobulin G1, anti-(human histocompatibility antigen HLA-DR) (human-
                                         mouse monoclonal Hu1 D10 γ1-chain), disulfide with human-mouse
                                         monoclonal Hu1D 10 light chain, dimer

    apolizumab                           immunoglobuline G1, anti-(antigène d’histocompatibilité HLA-DR humain)
                                         (chaîne γ1 de l’anticorps monoclonal de souris Hu1D 10 humanisé), dimère
                                         du disulfure avec la chaîne légère de l’anticorps monoclonal de souris
                                         Hu1D 10 humanisé

    apolizumab                           inmunoglobulina G1, anti-(antígeno de histocompatibilidad HLA-DR humano)
                                         (cadena γ1 del anticuerpo monoclonal humanizado de ratón Hu1D10),
                                         dímero del disulfuro con la cadena ligera del anticuerpo monoclonal
                                         humanizado de ratón Hu1D10




    asenapinum
    asenapine                            (3aRS,12bRS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-
                                         1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole

    asénapine                            (3aRS,12bRS)-5-chloro-2-méthyl-2,3,3a,12b-tétrahydro-
                                         1H-dibenzo[2,3:6,7]oxépino[4,5-c]pyrrole

    asenapina                            (3aRS,12bRS)-5-cloro-2-metil-2,3,3a,12b-tetrahidro-
                                         1H-dibenzo[2,3:6,7]oxepino[4,5-c]pirrol




                                                                                                                     117
Recommended INN: List 49                                                  WHO Drug Information, Vol. 17, No. 2, 2003




                           C17H16ClNO


                                                  CH 3
                                     H       N
                                                          and enantiomer
                                                          et énantiomère
                                             H
                                 O                        y enantiómero


                                                  Cl



axomadolum
axomadol                   (1RS,3RS,6RS)-6-[(dimethylamino)methyl]-
                           1-(3-methoxyphenyl)cyclohexane-1,3-diol

axomadol                   (1RS,3RS,6RS)-6-[(diméthylamino)méthyl]-
                           1-(3-méthoxyphényl)cyclohexane-1,3-diol

axomadol                   (1RS,3RS,6RS)-6-[(dimetilamino)metil]-
                           1-(3-metoxifenil)ciclohexano-1,3-diol

                           C26H25NO3


                                         CH3
                                         N
                                                 CH3
                                     H
                                                         and enantiomer
                                HO
                                                         et énantiomère
                                                         y enantiómero
                                                 H
                                         OH
                             OCH3




bifeprunoxum
bifeprunox                 7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]benzoxazol-2(3H)-one

biféprunox                 7-[4-(biphényl-3-ylméthyl)pipérazin-1-yl]benzoxazol-2(3H)-one

bifeprunox                 7-[4-(bifenil-3-ilmetil)piperazin-1-il]benzoxazol-2(3H)-ona

                           C24H23N3O2




                           HN            N
                                 O                   N
                            O




118
3   WHO Drug Information, Vol. 17, No. 2, 2003                                                  Recommended INN: List 49




    canertinibum
    canertinib                           N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-
                                         4-yl)propoxy]quinazolin-6-yl]prop-2-enamide

    canertinib                           N-[4-[(3-chloro-4-fluorophényl)amino]-7-[3-(morpholin-
                                         4-yl)propoxy]quinazolin-6-yl]prop-2-énamide

    canertinib                           N-[4-[(3-cloro-4-fluorofenil)amino]-7-[3-(morfolin-4-il)propoxi]quinazolin-
                                         6-il]prop-2-enamida

                                         C24H25ClFN5O3


                                                      O                 N

                                            N                               N
                                                     HN
                                                                      HN               Cl
                                            O             O
                                                 CH2
                                                                                       F




    cefovecinum
    cefovecin                            (6R,7R)-7-[[(2Z)-(2-aminothiazol-4-yl)(methoxyimino)acetyl]amino]-8-oxo-
                                         3-[(2S)-tetrahydrofuran-2-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
                                         2-carboxylic acid

    céfovécine                           acide (6R,7R)-7-[[(2Z)-(2-aminothiazol-4-yl)(méthoxyimino)acétyl]amino]-
                                         8-oxo-3-[(2S)-tétrahydrofuran-2-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ène-
                                         2-carboxylique

    cefovecina                           ácido (6R,7R)-7-[[(2Z)-(2-aminotiazol-4-il)(metoxiimino)acetil]amino]-8-oxo-
                                         3-[(2S)-tetrahidrofuran-2-il)-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxílico

                                         C17H19N5O6S2


                                                              CH3               CO2H
                                                              O     O
                                                          N                 N               O
                                                                  H                    H
                                                 N                N
                                          H2N                                   S
                                                                        H   H
                                                 S            O




                                                                                                                       119
Recommended INN: List 49                                                WHO Drug Information, Vol. 17, No. 2, 2003




cethromycinum
cethromycin                (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyl-3a,7,9,11,13,15-
                           hexamethyl-11-[[3-(quinolin-3-yl)prop-2-enyl]oxy]-10-[[3,4,6-trideoxy-
                           3-(dimethylamino)-β-D -xylo-hexopyranosyl]oxy]octahydro-
                           2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone

céthromycine               (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-éthyl-3a,7,9,11,13,15-
                           hexaméthyl-11-[[3-(quinoléin-3-yl)prop-2-ényl]oxy]-10-[[3,4,6-tridésoxy-
                           3-(diméthylamino)-β-D -xylo-hexopyranosyl]oxy]octahydro-
                           2H-oxacyclotétradécino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tétrone

cetromicina                (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-etil-3a,7,9,11,13,15-hexametil-
                           11-[[3-(quinolein-3-il)prop-2-enil]oxi]-10-[[3,4,6-tridesoxi-3-(dimetilamino)-
                           β-D -xilo-hexopiranosil]oxi]octahidro-2H-oxaciclotetradecino[4,3-d]oxazol-
                           2,6,8,14(1H,7H,9H)-tetrona

                           C42H59N3O10


                                    N                              O
                                                              H         CH3
                                                        H3C
                                                                            H
                                                                             CH3
                                                     O             H
                                                                              O
                                          CH3      H 3C            HN
                                                                   H
                                                O O                  O              O
                                    H3C       CH3   H             CH3 H
                                          N                                     CH 3
                                                          O                 O
                                                                  H CH3
                                                   OH


dabigatranum etexilatum
dabigatran etexilate       ethyl 3-[[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]=
                           methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-
                           2-yl)amino]propanoate

dabigatran étexilate       3-[[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminométhyl]phényl]amino]méthyl]-
                           1-méthyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoate
                           d’éthyle

dabigatrán etexilato       3-[[[2-[[[4-[[[(hexiloxi)carbonil]amino]iminometil]fenil]amino]metil]-1-metil-
                           1H-bencimidazol-5-il]carbonil](piridin-2-il)amino]propanoato de etilo

                           C34H41N7O5


                             O                      CH3
                                   O
                             N                                          O               O
                                              NH          N
                                                                            N               O   CH 3
                           H2N
                                                          N             N
                                                   H3C




120
3   WHO Drug Information, Vol. 17, No. 2, 2003                                              Recommended INN: List 49




    ecromeximabum
    ecromeximab                          immunoglobulin G1, anti-(GD3 ganglioside) (human-mouse monoclonal
                                         KM871 γ1-chain), disulfide with human-mouse monoclonal KM871 κ−chain,
                                         dimer

    écromeximab                          immunoglobuline G1, anti-(ganglioside GD3) (chaîne γ1 de l’anticorps
                                         monoclonal chimérique homme-souris KM871), dimère du disulfure avec la
                                         chaîne κ de l’anticorps monoclonal chimérique homme-souris KM871

    ecromeximab                          inmunoglobulina G1, anti-(gangliósido GD3) (cadena γ1 del anticuerpo
                                         monoclonal quimérico hombre-atón KM871), dímero del disulfuro con la
                                         cadena κ del anticuerpo monoclonal quimérico hombre-ratón KM871




    eculizumabum
    eculizumab                           immunoglobulin, anti-(human complement C5 α-chain) (human-mouse
                                         monoclonal 5G1.1 heavy chain), disulfide with human-mouse monoclonal
                                         5G1.1 light chain, dimer

    éculizumab                           immunoglobuline, anti-(chaîne α du complément C5 humain) (chaîne lourde
                                         de l’anticorps monoclonal de souris 5G1.1 humanisé), dimère du disulfure
                                         avec la chaîne légère de l’anticorps monoclonal de souris 5G1.1 humanisé

    eculizumab                           inmunoglobulina, anti-(cadena α del complemento C5 humano) (cadena
                                         pesada del anticuerpo monoclonal humanizado de ratón 5G1.1), dímero del
                                         disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de
                                         ratón 5G1.1




    elzasonanum
    elzasonan                            (2Z)-4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-
                                         1-yl)benzylidene]thiomorpholin-3-one

    elzasonan                            (2Z)-4-(3,4-dichlorophényl)-2-[2-(4-méthylpipérazin-
                                         1-yl)benzylidène]thiomorpholin-3-one

    elzasonán                            (2Z)-4-(3,4-diclorofenil)-2-[2-(4-metilpiperazin-1-il)bencilideno]tiomorfolin-
                                         3-ona

                                         C22H23Cl2N3OS


                                            CH3
                                            N
                                                                 Cl
                                                                       Cl
                                            N            O

                                                             N
                                                     S




                                                                                                                          121
Recommended INN: List 49                                                WHO Drug Information, Vol. 17, No. 2, 2003




enecadinum
enecadin                   4-(4-fluorophenyl)-2-methyl-6-[[5-(piperidin-1-yl)pentyl]oxy]pyrimidine

énécadine                  4-(4-fluorophényl)-2-méthyl-6-[[5-(pipéridin-1-yl)pentyl]oxy]pyrimidine

enecadina                  4-(4-fluorofenil)-2-metil-6-[[5-(piperidin-1-il)pentil]oxi]pirimidina

                           C21H28FN3O

                                                                 CH3

                                                             N     N

                                  N                      O

                                                                               F

ertiprotafibum
ertiprotafib               (2R)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl)-
                           2,6-dimethylphenoxy]-3-phenylpropanoic acid

ertiprotafib               acide (2R)-2-[4-(9-bromo-2,3-diméthylnaphto[2,3-b]thiophén-4-yl)-
                           2,6-diméthylphénoxy]-3-phénylpropanoïque

ertiprotafib               ácido (2R)-2-[4-(9-bromo-2,3-dimetilnafto[2,3-b]tiofen-4-il)-
                           2,6-dimetilfenoxi]-3-fenilpropanoico

                           C31H27BrO3S

                                                 CH 3
                           H3C        CH3                O       CO2H

                              S                           H
                                                         CH3

                            Br




eszopiclonum
eszopiclone                (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-
                           5-yl-4-methylpiperazine-1-carboxylate

eszopiclone                4-méthylpipérazine-1-carboxylate de (5S)-6-(5-chloropyridin-2-yl)-7-oxo-
                           6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yle

eszopiclona                4-metilpiperazina-1-carboxilato de (5S)-6-(5-cloropiridin-2-il)-7-oxo-
                           6,7-dihidro-5H-pirrolo[3,4-b]pirazin-5-ilo

                           C17H17ClN6O3

                                             O
                                                                   Cl
                                        N        O
                                             H
                                  N
                           H3C                       N       N
                                         N

                                                         O
                                             N




122
3   WHO Drug Information, Vol. 17, No. 2, 2003                                               Recommended INN: List 49




    fandosentanum
    fandosentan                          4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
                                         2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide

    fandosentan                          1,1-dioxyde de l’acide 4-(7-éthyl-1,3-benzodioxol-5-yl)-
                                         2-[2-(trifluorométhyl)phényl]-2H-1,2-benzothiazine-3-carboxylique

    fandosentán                          1,1-dióxido del ácido 4-(7-etil-1,3-benzodioxol-5-il)-2-[2-(trifluorometil)fenil]-
                                         2H-1,2-benzotiazina-3-carboxílico

                                         C25H18F3NO6S

                                                                      CH3

                                                                           O
                                                           CO2H

                                                       N                   O

                                          F 3C O       S
                                                   O




    fontolizumabum
    fontolizumab                         immunoglobulin G1, anti-(human interferon γ) (human-mouse monoclonal
                                         HuZAF γ1-chain), disulfide with human-mouse monoclonal HuZAF light
                                         chain, dimer

    fontolizumab                         immunoglobuline G1, anti-(interféron γ humain) (chaîne γ1 de l’anticorps
                                         monoclonal de souris HuZAF humanisé), dimère du disulfure avec la
                                         chaîne légère de l’anticorps monoclonal de souris HuZAF humanisé

    fontolizumab                         inmunoglobulina G1, anti-(interferón γ humano) (cadena γ1 del anticuerpo
                                         monoclonal humanizado de ratón HuZAF), dímero del disulfuro con la
                                         cadena ligera del anticuerpo monoclonal humanizado de ratón HuZAF



    garenoxacinum
    garenoxacin                          1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-
                                         1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

    garénoxacine                         acide 1-cyclopropyl-8-(difluorométhoxy)-7-[(1R)-1-méthyl-2,3-dihydro-
                                         1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

    garenoxacina                         ácido 1-ciclopropil-8-(difluorometoxi)-7-[(1R)-1-metil-2,3-dihidro-
                                         1H-isoindol-5-il]-4-oxo-1,4-dihidroquinolina-3-carboxílico

                                         C23H20F2N2O4

                                                 HN
                                           H               F2HC
                                                                  O
                                          H3C
                                                                       N


                                                                               CO2H
                                                                       O



                                                                                                                        123
Recommended INN: List 49                                                            WHO Drug Information, Vol. 17, No. 2, 2003




inecalcitolum
inecalcitol                (7E)-19-nor-9,10-seco-14β-cholesta-5,7-dien-23-yne-1α,3β,25-triol

inécalcitol                (7E)-19-nor-9,10-séco-14β-cholesta-5,7-dién-23-yne-1α,3β,25-triol

inecalcitol                (7E)-19-nor-9,10-seco-14β-colesta-5,7-dien-23-ino-1α,3β,25-triol

                           C26H40O3

                                                H3C H
                                                CH3
                                                             H
                                                                            OH
                                                                             CH 3
                                                                     H3C
                                                H




                           HO                   OH
                                H           H

iroxanadinum
iroxanadine                (-)-5-(piperidin-1-ylmethyl)-3-(pyridin-3-yl)-5,6-dihydro-2H-1,2,4-oxadiazine

iroxanadine                (-)-5-(pipéridin-1-ylméthyl)-3-(pyridin-3-yl)-5,6-dihydro-2H-1,2,4-oxadiazine

iroxanadina                (-)-5-(piperidin-1-ilmetil)-3-(piridin-3-il)-5,6-dihidro-2H-1,2,4-oxadiazina

                           C14H20N4O


                                                O
                                                        NH
                                                                           or enantiomer
                                    N                                      ou énantiomère
                                                N
                                            H                              o enantiómero
                                                                 N



lidorestatum
lidorestat                 [3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]-1H-indol-1-yl]acetic acid

lidorestat                 acide [3-[(4,5,7-trifluorobenzothiazol-2-yl)méthyl]-1H-indol-1-yl]acétique

lidorestat                 ácido [3-[(4,5,7-trifluorobenzotiazol-2-il)metil]-1H-indol-1-il]acético

                           C18H11F3N2O2S


                                                CO2H
                                        N

                                                                 F
                                                    N
                                                                       F
                                                 S

                                                         F


124
3   WHO Drug Information, Vol. 17, No. 2, 2003                                                              Recommended INN: List 49




    liraglutidum
    liraglutide                          N26 -(hexadecanoyl-γ-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide

    liraglutide                          N26 -(hexadécanoyl-γ-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide

    liraglutida                          N26-(hexadecanoil-γ-glutamilo)-[34-arginina]GLP-1-(7-37)-péptido

                                         C172H265N43O51


                                          H    His        Ala     Glu     Gly    Thr    Phe    Thr    Ser   Asp    Val   Ser
                                                  7                        10

                                           H3C
                                                                                                            Glu OH
                                                                                                        O
                                               Ser        Tyr      Leu     Glu   Gly     Gln    Ala   Ala Lys     Glu    Phe
                                                                   20
                                               Ile        Ala     Trp     Leu    Val    Arg    Gly    Arg   Gly   OH
                                                          30                                                37




    lubiprostonum
    lubiprostone                         (-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-
                                         6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid

    lubiprostone                         (-)-acide 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-
                                         6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoïque

    lubiprostona                         (-)-ácido 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentil)-2-hidroxi-
                                         6-oxooctahidrociclopenta[b]piran-5-il]heptanoico

                                         C20H32F2O5


                                              O       H
                                                                                 CO2H

                                                              H
                                          H
                                              O

                                          HO
                                                  F       F              CH3




    lumiracoxibum
    lumiracoxib                          [2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl]acetic acid

    lumiracoxib                          acide [2-[(2-chloro-6-fluorophényl)amino]-5-méthylphényl]acétique

    lumiracoxib                          ácido [2-[(2-cloro-6-fluorofenil)amino]-5-metilfenil]acético




                                                                                                                                125
Recommended INN: List 49                                                  WHO Drug Information, Vol. 17, No. 2, 2003




                           C15H13ClFNO2


                           H3C
                                             CO2H

                                            NH
                                   F                 Cl




merimepodibum
merimepodib                (3S)-tetrahydrofuran-3-yl [3-[[[3-methoxy-4-(oxazol-
                           5-yl)phenyl]carbamoyl]amino]benzyl]carbamate

mérimépodib                [3-[[[3-méthoxy-4-(oxazol-5-yl)phényl]carbamoyl]amino]benzyl]carbamate
                           de (3S)-tétrahydrofuran-3-yle

merimepodib                [3-[[[3-metoxi-4-(oxazol-5-il)fenil]carbamoil]amino]bencil]carbamato de
                           (3S)-tetrahidrofuran-3-ilo

                           C23H24N4O6


                            N

                             O                       O
                                                                           H
                                                                           N       O
                            H3CO                 N        N
                                                 H        H                        H       O
                                                                               O



mozavaptanum
mozavaptan                 N-[4-[[(5RS)-5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-
                           1-yl]carbonyl]phenyl]-2-methylbenzamide

mozavaptan                 N-[4-[[(5RS)-5-(diméthylamino)-2,3,4,5-tétrahydro-1H-1-benzazépin-
                           1-yl]carbonyl]phényl]-2-méthylbenzamide

mozavaptán                 N-[4-[[(5RS)-5-(dimetilamino)-2,3,4,5-tetrahidro-1H-1-benzazepin-
                           1-il]carbonil]fenil]-2-metilbenzamida

                           C27H29N3O2

                                                          O

                                   O                          N                    and enantiomer
                                                                                   et énantiomère
                                        N                                  CH3     y enantiómero
                                        H                             N
                                                                  H
                                   CH3                                CH 3




126
3   WHO Drug Information, Vol. 17, No. 2, 2003                                                   Recommended INN: List 49




    nalfurafinum
    nalfurafine                          (E)-N-[17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6β-yl]-
                                         3-(furan-3-yl)-N-methylprop-2-enamide

    nalfurafine                          (E)-N-[17-(cyclopropylméthyl)-4,5α-époxy-3,14-dihydroxymorphinan-6β-yl]-
                                         3-(furan-3-yl)-N-méthylprop-2-énamide

    nalfurafina                          (E)-N-[17-(ciclopropilmetil)-4,5α-epoxi-3,14-dihidroximorfinan-6β-il]-
                                         3-(furan-3-il)-N-metilprop-2-enamida

                                         C28H32N2O5



                                                    H     N

                                                    HO
                                                                       O

                                                      O            N
                                          HO              H H
                                                                   CH3             O


    naminidilum
    naminidil                            N-cyano-N’-(4-cyanophenyl)-N’’-[(1R)-1,2,2-trimethylpropyl]guanidine

    naminidil                            N-cyano-N’-(4-cyanophényl)-N’’-[(1R)-1,2,2-triméthylpropyl]guanidine

    naminidil                            N-ciano-N’-(4-cianofenil)-N’’-[(1R)-1,2,2-trimetilpropil]guanidina

                                         C15H19N5


                                                              CN
                                          NC
                                                              N    H CH3
                                                                            CH 3
                                                          N        N
                                                          H        HH C    CH 3
                                                                     3



    nemifitidum
    nemifitide                           4-fluoro- L -phenylalanyl-trans-4-hydroxy- L -prolyl- L -arginylglycyl-
                                         L -tryptophanamide


    némifitide                           (4-fluoro- L -phénylalanyl)-(trans-4-hydroxy-L -prolyl)- L -arginyl-glycyl-
                                         L -tryptophanamide


    nemifitida                           (4-fluoro- L-fenilalanil)-(trans-4-hidroxi-L -prolil)- L-arginilglicil- L-triptofanamida




                                                                                                                              127
Recommended INN: List 49                                                          WHO Drug Information, Vol. 17, No. 2, 2003




                           C33H43FN10O6


                                                                    NH2
                                                       HN
                                                                    NH                     NH


                                                  O            H              O        H
                                     O                               H
                                             H
                                                                     N                      NH2
                           H2N                         N                           N
                                         N
                                                       H                           H
                                 H                             O                        O

                                                  OH
                                             H


                           F




nortopixantronum
nortopixantrone            2-[2-[(2-hydroxyethyl)amino]ethyl]-
                           5-[[2-(methylamino)ethyl]amino]indazolo[4,3-gh]isoquinolin-6(2H)-one

nortopixantrone            2-[2-[(2-hydroxyéthyl)amino]éthyl]-
                           5-[[2-(méthylamino)éthyl]amino]indazolo[4,3-gh]isoquinoléin-6(2H)-one

nortopixantrona            2-[2-[(2-hidroxietil)amino]etil]-
                           5-[[2-(metilamino)etil]amino]indazolo[4,3-gh]isoquinolin-6(2H)-ona

                           C20H24N6O2


                                                           H
                                                           N
                                         N N                             OH

                           N



                                     O       HN                    CH3
                                                           N
                                                           H




128
3   WHO Drug Information, Vol. 17, No. 2, 2003                                                 Recommended INN: List 49




    oblimersenum
    oblimersen                           P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-
                                         (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-
                                         2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-
                                         P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-
                                         P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-
                                         (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-
                                         2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-
                                         P-thioadenylyl-(3'→5')-thymidine

    oblimersen                           P-thiothymidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-
                                         (3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-
                                         2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-
                                         2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-
                                         2'-désoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-
                                         P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-
                                         P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-
                                         P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-thymidine

    oblimerseno                          P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-
                                         2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-
                                         P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-
                                         (3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-
                                         P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-
                                         (3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-
                                         2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-timidina

                                         C172H221N62O91P17S17




    ortataxelum
    ortataxel                            (3aS,4R,5E,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis(acetyloxy)-
                                         13-(benzoyloxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-
                                         3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano-
                                         13aH-oxeto[2'’,3'’:5',6']benzo[1',2':4,5]cyclodeca[1,2-d]-1,3-dioxol-4-yl
                                         (2R,3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-
                                         5-methylhexanoate

    ortataxel                            (2R,3S)-3-[[(1,1-diméthyléthoxy)carbonyl]amino]-2-hydroxy-
                                         5-méthylhexanoate de (3aS,4R,5E,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-
                                         7,12a-bis(acétyloxy)-13-(benzoyloxy)-9-hydroxy-5,8a,14,14-tétraméthyl-
                                         2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodécahydro-
                                         6,13a-méthano-13aH-oxéto[2'’,3'’:5',6']benzo[1',2':4,5]cyclodéca[1,2-d]-
                                         1,3-dioxol-4-yle

    ortataxel                            (2R,3S)-3-[[(1,1-dimetiletoxi)carbonil]amino]-2-hidroxi-5-metilhexanoato de
                                         (3aS,4R,5E,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis(acetiloxi)-
                                         13-(benzoiloxi)-9-hidroxi-5,8a,14,14-tetrametil-2,8-dioxo-
                                         3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahidro-6,13a-metano-
                                         13aH-oxeto[2'’,3'’:5',6']benzo[1',2':4,5]ciclodeca[1,2-d]-1,3-dioxol-4-ilo




                                                                                                                            129
Recommended INN: List 49                                                  WHO Drug Information, Vol. 17, No. 2, 2003




                           C44H57NO17

                                                        O         CH3
                                                                  H       O
                                                             O                   OH
                                                H3C                           CH3 H
                                         H OH
                           H 3C                 O                      CH3
                                                                                  H     H
                                                H                      CH3
                                  CH3 H NH O        H
                                    O                                         O         O
                                                        O         O
                                         O                            H O
                                  H3 C                                   O        CH3
                                                                  O
                                  H3 C                      O
                                         CH 3




osemozotanum
osemozotan                 3-(1,3-benzodioxol-5-yloxy)-N-[[(2S)-2,3-dihydro-1,4-benzodioxin-
                           2-yl]methyl]propan-1-amine

osémozotan                 3-(1,3-benzodioxol-5-yloxy)-N-[[(2S)-2,3-dihydro-1,4-benzodioxin-
                           2-yl]méthyl]propan-1-amine

osemozotán                 3-(1,3-benzodioxol-5-iloxi)-N-[[(2S)-2,3-dihidro-1,4-benzodioxin-
                           2-il]metil]propan-1-amina

                           C19H21NO5


                                                            H H           O
                             O            O                 N
                                                                      O
                             O




pascolizumabum
pascolizumab               immunoglobulin G1, anti-(human interleukin 4) (human-mouse monoclonal
                           SB-240683 γ1-chain), disulfide with human-mouse monoclonal SB-240683
                           κ−chain, dimer

pascolizumab               immunoglobuline G1, anti-(interleukine 4 humaine) (chaîne γ1 de l’anticorps
                           monoclonal de souris SB-240683 humanisé), dimère du disulfure avec la
                           chaîne κ de l’anticorps monoclonal de souris SB-240683 humanisé

pascolizumab               inmunoglobulina G1, anti-(interleukina 4 humana) (cadena γ1 del anticuerpo
                           monoclonal humanizado de ratón SB-240683), dímero del disulfuro con la
                           cadena κ del anticuerpo monoclonal humanizado de ratón SB-240683




130
3   WHO Drug Information, Vol. 17, No. 2, 2003                                                  Recommended INN: List 49




    pegaptanibum
    pegaptanib                           5'-ester of (2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-
                                         (2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-
                                         2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-
                                         2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-
                                         (2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-
                                         (3'→3')-dT with α,α’-[[(1S)-1-[[5-(phosphonooxy)pentyl]carbamoyl]pentane-
                                         1,5-diyl]bis(iminocarbonyl)]bis[ω-methoxypoly(oxyethane-1,2-diyl)]

    pégaptanib                           (2'-désoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-désoxy-2'-fluoro)U-(2'-désoxy-
                                         2'-fluoro)C-Am-Gm-(2'-désoxy-2'-fluoro)U-Gm-Am-Am-(2'-désoxy-
                                         2'-fluoro)U-Gm-(2'-désoxy-2'-fluoro)C-(2'-désoxy-2'-fluoro)U-(2'-désoxy-
                                         2'-fluoro)U-Am-(2'-désoxy-2'-fluoro)U-Am-(2'-désoxy-2'-fluoro)C-Am-
                                         (2'-désoxy-2'-fluoro)U-(2'-désoxy-2'-fluoro)C-(2'-désoxy-2'-fluoro)C-Gm-
                                         (3'→3')-dT 5'-estérifié par α,α’-[[(1S)-1-[[5-phosphonooxy)pentyl]=
                                         carbamoyl]pentane-1,5-diyl]bis(iminocarbonyl)]bis[ω-méthoxypoly=
                                         (oxyéthane-1,2-diyl)]

    pegaptanib                           (2'-desoxi-2'-fluoro)C-Gm-Gm-A-A-(2'-desoxi-2'-fluoro)U-(2'-desoxi-
                                         2'-fluoro)C-Am-Gm-(2'-desoxi-2'-fluoro)U-Gm-Am-Am-(2'-desoxi-
                                         2'-fluoro)U-Gm-(2'-desoxi-2'-fluoro)C-(2'-desoxi-2'-fluoro)U-(2'-desoxi-
                                         2'-fluoro)U-Am-(2'-desoxi-2'-fluoro)U-Am-(2'-desoxi-2'-fluoro)C-Am-
                                         (2'-desoxi-2'-fluoro)U-(2'-desoxi-2'-fluoro)C-(2'-desoxi-2'-fluoro)C-Gm-
                                         (3'→3')-dT 5'-esterificado con α,α’-[[(1S)-1-[[5-(fosfonooxi)pentil]=
                                         carbamoil]pentano-1,5-diil]bis(iminocarbonil)]bis[ω-metoxipoli(oxietano-
                                         1,2-diilo)]

                                         C294H370F13N107O188P28[C2H4O]n


                                                 x+y=n                            O
                                                                                          O
                                                                              N       O        CH 3
                                                                              H           y
                                                             O
                                                                 H        H                           RNA
                                                 O                        N               O
                                          H3C            O     N                               P
                                                             x H
                                                                      O                       O OH




    pegsunerceptum
    pegsunercept                         pegylated L-methionyl-1-105-human tumor necrosis factor receptor p55

    pegsunercept                         L-méthionyl-1-105-récepteur p55 du facteur de nécrose tumorale humain,
                                         pegylé

    pegsunercept                         L-metionil-1-105-receptor p55 del factor de necrosis tumoral humano,
                                         pegilado




                                                                                                                    131
Recommended INN: List 49                                             WHO Drug Information, Vol. 17, No. 2, 2003




                           C502H758N154O165S16 (protein portion)




perflubrodecum
perflubrodec               1-bromohenicosafluorodecane

perflubrodec               1-bromohénicosafluorodécane

perflubrodec               1-bromohenicosafluorodecano

                           C10BrF21

                                      F   F F   F F   F F   F
                           F3C                                  Br

                                 F    F F   F F   F F   F F     F


                                                                                                                  DSVCPQGKY

                                                                                                                  CRECESGSFT

                                                                                                                  RDTVCGCRKN
picoplatinum
picoplatin                 (SP-4-3)-amminedichloro(2-methylpyridine)platinium

picoplatine                (SP-4-3)-amminedichloro(2-méthylpyridine)platine

picoplatino                (SP-4-3)-aminodicloro(2-metilpiridina)platino

                           C6H10Cl2N2Pt


                            H3 C

                           Cl         N
                                 Pt
                           Cl         NH3




132
3   WHO Drug Information, Vol. 17, No. 2, 2003                                               Recommended INN: List 49




    plevitrexedum
    plevitrexed                          (2S)-2-[[4-[[(2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl](prop-
                                         2-ynyl)amino]-2-fluorobenzoyl]amino]-4-(1H-tetrazol-5-yl)butanoic acid

    plévitrexed                          acide (2S)-2-[[4-[[(2,7-diméthyl-4-oxo-1,4-dihydroquinazolin-
                                         6-yl)méthyl](prop-2-ynyl)amino]-2-fluorobenzoyl]amino]-4-(1H-tétrazol-
                                         5-yl)butanoïque

    plevitrexed                          ácido (2S)-2-[[4-[[(2,7-dimetil-4-oxo-1,4-dihidroquinazolin-6-il)metil](prop-
                                         2-inil)amino]-2-fluorobenzoil]amino]-4-(1H-tetrazol-5-il)butanoico

                                         C26H25FN8O4


                                                                                O   H CO2H

                                                     O                              N
                                                                                    H        H
                                                                                             N
                                                 N                 N            F
                                                                                                 N
                                                                                         N N
                                          H 3C       N           CH3
                                                     H                     CH


    pumosetragum
    pumosetrag                           N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-
                                         6-carboxamide

    pumosétrag                           N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-oxo-4,7-dihydrothiéno[3,2-b]pyridine-
                                         6-carboxamide

    pumosetrag                           N-[(3R)-1-azabiciclo[2.2.2]oct-3-il]-7-oxo-4,7-dihidrotieno[3,2-b]piridina-
                                         6-carboxamida

                                         C15H17N3O2S


                                                     H
                                                     N
                                                             H
                                                             N
                                           S
                                                             H
                                                     O   O             N



    siplizumabum
    siplizumab                           immunolobulin G1, anti-(human CD2 (antigen)) (human-rat monoclonal
                                         MEDI-507 γ1-chain), disulfide with human-rat monoclonal MEDI-507 light
                                         chain, dimer

    siplizumab                           immunolobuline G1, anti-(antigène humain CD2) (chaîne γ1 de l’anticorps
                                         monoclonal de rat MEDI-507 humanisé), dimère du disulfure avec la chaîne
                                         légère de l’anticorps monoclonal de rat MEDI-507 humanisé

    siplizumab                           inmunolobulina G1, anti-(antígeno humano CD2) (cadena γ1 del anticuerpo
                                         monoclonal de rata humanizado MEDI-507), dímero del disulfuro con la
                                         cadena ligera del anticuerpo monoclonal de rata humanizado MEDI-507




                                                                                                                         133
Recommended INN: List 49                                              WHO Drug Information, Vol. 17, No. 2, 2003




soraprazanum
soraprazan                 (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-
                           7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphtyridin-8-ol

soraprazan                 (7R,8R,9R)-7-(2-méthoxyéthoxy)-2,3-diméthyl-9-phényl-
                           7,8,9,10-tétrahydroimidazo[1,2-h][1,7]naphtyridin-8-ol

soraprazán                 (7R,8R,9R)-9-fenil-2,3-dimetil-7-(2-metoxietoxi)-
                           7,8,9,10-tetrahidroimidazo[1,2-h][1,7]naftiridin-8-ol

                           C21H25N3O3


                                                              CH3
                                                      N
                                          H H
                                            N                   CH3
                                                          N
                                      H
                                     HO
                                                  H
                           H3C                O
                                 O




tapentadolum
tapentadol                 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol

tapentadol                 3-[(1R,2R)-3-(diméthylamino)-1-éthyl-2-méthylpropyl]phénol

tapentadol                 3-[(1R,2R)-3-(dimetilamino)-1-etil-2-metilpropil]fenol

                           C14H23NO


                                   H 3C       CH3
                                          N
                                     H
                              H3 C
                                          H
                                              CH3


                              OH




tecadenosonum
tecadenoson                9-β-D -ribofuranosyl-N-[(3R)-tetrahydrofuran-3-yl]-9H-purin-6-amine

técadénoson                9-β-D -ribofuranosyl-N-[(3R)-tétrahydrofuran-3-yl]-9H-purin-6-amine

tecadenosón                9-β-D -ribofuranosil-N-[(3R)-tetrahidrofuran-3-il]-9H-purin-6-amina




134
3   WHO Drug Information, Vol. 17, No. 2, 2003                                            Recommended INN: List 49




                                         C14H19N5O5



                                                     H
                                                 HN            O

                                                           N
                                                 N

                                          HO         N     N
                                                      O




                                                 OH       OH




    tecalcetum
    tecalcet                             3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine

    técalcet                             3-(2-chlorophényl)-N-[(1R)-1-(3-méthoxyphényl)éthyl]propan-1-amine

    tecalcet                             3-(2-clorofenil)-N-[(1R)-1-(3-metoxifenil)etil]propan-1-amina

                                         C18H22ClNO

                                                               H CH3
                                                                        OCH3
                                                               N
                                                               H
                                                     Cl




    teneliximabum
    teneliximab                          immunoglobulin G1, anti-(human CD40 (antigen)) (human-mouse monoclonal
                                         chi220 γ1-chain), disulfide with human-mouse monoclonal chi220 light
                                         chain, dimer

    ténéliximab                          immunoglobuline G1, anti-(antigène CD40 humain) (chaîne γ1 de l’anticorps
                                         monoclonal chimérique homme souris chi220), dimère du disulfure avec la
                                         chaîne légère de l’anticorps monoclonal chimérique homme souris chi220

    teneliximab                          inmunoglobulina G1, anti-(antígeno CD40 humano) (cadena γ1 del
                                         anticuerpo monoclonal quimérico hombre ratón chi220), dímero del disulfuro
                                         con la cadena ligera del anticuerpo monoclonal quimèrico hombre ratón
                                         chi220




                                                                                                                135
Recommended INN: List 49                                                  WHO Drug Information, Vol. 17, No. 2, 2003




topixantronum
topixantrone               5-[[2-(dimethylamino)ethyl]amino]-
                           2-[2-[(2-hydroxyethyl)amino]ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one

topixantrone               5-[[2-(diméthylamino)éthyl]amino]-
                           2-[2-[(2-hydroxyéthyl)amino]éthyl]indazolo[4,3-gh]isoquinoléin-6(2H)-one

topixantrona               5-[[2-(dimetilamino)etil]amino]-
                           2-[2-[(2-hidroxietil)amino]etil]indazolo[4,3-gh]isoquinolin-6(2H)-ona

                           C21H26N6O2

                                                        H
                                                        N
                                        N N                         OH

                           N



                                    O      HN               CH3
                                                        N
                                                        CH3



toralizumabum
toralizumab                immunoglobulin G1, anti-(human CD40 ligand) (human-mouse monoclonal
                           IDEC-131 γ1-chain), disulfide with human-mouse monoclonal IDEC-131
                           κ−chain, dimer

toralizumab                immunoglobuline G1, anti-(ligand CD40 humain) (chaîne γ1 de l’anticorps
                           monoclonal de souris IDEC-131 humanisé), dimère du disulfure avec la
                           chaîne κ de l’anticorps monoclonal de souris IDEC-131 humanisé

toralizumab                inmunoglobulina G1, anti-(ligando CD40 humano) (cadena γ1 del anticuerpo
                           monoclonal humanizado de ratón IDEC-131), dímero del disulfuro con la
                           cadena κ del anticuerpo monoclonal humanizado de ratón IDEC-131



torcetrapibum
torcetrapib                ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino]-
                           2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate

torcétrapib                (2R,4S)-4-[[3,5-bis(trifluorométhyl)benzyl](méthoxycarbonyl)amino]-2-éthyl-
                           6-(trifluorométhyl)-3,4-dihydroquinoléine-1(2H)-carboxylate d’éthyle

torcetrapib                (2R,4S)-4-[[3,5-bis(trifluorometil)bencil](metoxicarbonil)amino]-2-etil-
                           6-(trifluorometil)-3,4-dihidroquinolina-1(2H)-carboxilato de etilo

                           C26H25F9N2O4

                                          F3C
                                                                O

                                                            N       O     CH3
                                                                H
                           F3 C                                     CH3
                                                N
                                                    H
                                                        CH3
                                           O        O
                                   CF 3

136
3   WHO Drug Information, Vol. 17, No. 2, 2003                                            Recommended INN: List 49




    torcitabinum
    torcitabine                          4-amino-1-(2-deoxy-β-L -erythro-pentofuranosyl)pyrimidin-2(1H)-one

    torcitabine                          4-amino-1-(2-désoxy-β-L -érythro-pentofuranosyl)pyrimidin-2(1H)-one

    torcitabina                          4-amino-1-(2-desoxi-β-L -eritro-pentofuranosil)pirimidin-2(1H)-ona

                                         C9H13N3O4


                                                          O
                                                   OH

                                          HO                  N       O

                                                                  N

                                                              NH2




    treprostinilum
    treprostinil                         [[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-
                                         hexahydro-1H-cyclopenta[b]naphthalen-5-yl]oxy]acetic acid

    tréprostinil                         acide [[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-
                                         hexahydro-1H-cyclopenta[b]naphtalén-5-yl]oxy]acétique

    treprostinilo                        ácido [[(1R,2R,3aS,9aS)-2-hidroxi-1-[(3S)-3-hidroxioctil]-2,3,3a,4,9,9a-
                                         hexahidro-1H-ciclopenta[b]naftalen-5-il]oxi]acético

                                         C23H34O5



                                                                  O       CO 2H
                                                          H
                                          HO
                                           H
                                               H          H


                                                 HO
                                                                          CH3
                                                      H




    triplatinum tetranitras
    triplatin tetranitrate               trans-[bis[trans-diamminechloroplatinium(µ-hexane-
                                         1,6-diamine)]]diammineplatinium tetranitrate

    tétranitrate de triplatine           tétranitrate de trans-[bis[trans-diamminechloroplatine(µ-hexane-
                                         1,6-diamine)]]diammineplatine

    tetranitrato de triplatino           tetranitrato de trans-[bis[trans-diaminacloroplatino(µ-hexano-
                                         1,6-diamina)]]diaminaplatino



                                                                                                                    137
Recommended INN: List 49                                          WHO Drug Information, Vol. 17, No. 2, 2003




                           C12H50Cl2N14O12Pt3


                                                                                                     4+
                                                                  H2              H 3N         Cl
                                                     H3N          N                       Pt
                                        H2
                                                             Pt                      N         NH3
                              Cl        N                                            H2
                                   Pt                   N         NH3
                            H3N         NH3             H2


                                                           4 NO3 -




tulathromycinum
tulathromycin              Mixture of two compounds (in equilibrium in solution):
                           tulathromycinum A
                           (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-
                           3-O-methyl-4-C-[(propylamino)methyl]-α-L -ribo-hexopyranosyl)oxy]-2-ethyl-
                           3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-
                           3-(dimethylamino)-β-D -xylo-hexopyranosyl]oxy]-1-oxa-
                           6-azacyclopentadecan-15-one
                           tulathromycinum B
                           (2R,3R,6R,8R,9R,10S,11S,12R)-11-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
                           4-C-[(propylamino)methyl]-α-L -ribo-hexopyranosyl)oxy]-2-[(1R,2R)-
                           1,2-dihydroxy-1-methylbutyl]-8-hydroxy-3,6,8,10,12-pentamethyl-
                           9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-
                           4-azacyclotridecan-13-one

tulathromycine             Mélange de deux composés (en équilibre en solution):
                           tulathromycinum A
                           (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-didésoxy-3-C-méthyl-
                           3-O-méthyl-4-C-[(propylamino)méthyl]-α-L -ribo-hexopyranosyl)oxy]-2-éthyl-
                           3,4,10-trihydroxy-3,5,8,10,12,14-hexaméthyl-11-[[3,4,6-tridésoxy-
                           3-(diméthylamino)-β-D -xylo-hexopyranosyl]oxy]-1-oxa-
                           6-azacyclopentadécan-15-one
                           tulathromycinum B
                           (2R,3R,6R,8R,9R,10S,11S,12R)-11-[(2,6-didésoxy-3-C-méthyl-3-O-méthyl-
                           4-C-[(propylamino)méthyl]-α-L -ribo-hexopyranosyl)oxy]-2-[(1R,2R)-
                           1,2-dihydroxy-1-méthylbutyl]-8-hydroxy-3,6,8,10,12-pentaméthyl-
                           9-[[3,4,6-tridésoxy-3-(diméthylamino)-β-D -xylo-hexopyranosyl]oxy]-1-oxa-
                           4-azacyclotridécan-13-one

tulatromicina              Mezcla de dos componentes (en equilibrio en solución):
                           tulathromycinum A
                           (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-didesoxi-3-C-metil-3-O-
                           metil-4-C-[(propilamino)metil]-α-L -ribo-hexopiranosil)oxi]-2-etil-3,4,10-
                           trihidroxi-3,5,8,10,12,14-hexametil-11-[[3,4,6-tridesoxi-3-(dimetilamino)-
                           β-D -xilo-hexopiranosil]oxi]-1-oxa-6-azaciclopentadecan-15-ona
                           tulathromycinum B
                           (2R,3R,6R,8R,9R,10S,11S,12R)-11-[(2,6-didesoxi-3-C-metil-3-O-metil-4-C-[
                           (propilamino)metil]-α-L -ribo-hexopiranosil)oxi]-2-[(1R,2R)-1,2-dihydroxi-
                           1-metilbutil]-8-hidroxi-3,6,8,10,12-pentametil-9-[[3,4,6-tridesoxi-3-
                           (dimetilamino)-β-D -xilo-hexopiranosil]oxi]-1-oxa-4-azaciclotridecan-13-ona




138
3   WHO Drug Information, Vol. 17, No. 2, 2003                                                          Recommended INN: List 49




                                         C41H79N3O12 tulathromycinum A
                                         C41H79N3O12 tulathromycinum B


                                          tulathromycinum A           H3C              NH CH3
                                                                       H                   H
                                                                    H3C              H     OH
                                                 CH3               HO               HO        CH3
                                                       O O                           CH3      H
                                          H3C        CH3                                O
                                                 N                      H            H          CH3
                                                                       O O
                                                            HO
                                                                                            O
                                                                 CH3          H
                                                       OH        OCH3               H CH3
                                            H3C
                                                        N
                                                        H        CH3



                                          tulathromycinum B                  H 3C
                                                                             H
                                                                       H3C                      CH3
                                                                                      HN
                                                 CH3               HO                            H OH
                                                                                                 H
                                                       O O                           CH3                 CH 3
                                          H3C        CH3                               O
                                                 N                      H            H   H        CH3
                                                                       O O                      OH
                                                            HO
                                                                                            O
                                                                 CH3          H
                                                       OH        OCH3               H CH3
                                            H 3C
                                                        N
                                                        H        CH3




    vapaliximabum
    vapaliximab                          immunoglobulin G2, anti-(human vascular adhesion protein VAP-1) (human-
                                         mouse monoclonal 2D10 γ2-chain), disulfide with human-mouse monoclonal
                                         2D10 κ−chain, dimer

    vapaliximab                          immunoglobuline G2, anti-(protéine d’adhésion vasculaire humaine VAP-1)
                                         (chaîne γ2 de l’anticorps monoclonal chimérique homme-souris 2D10),
                                         dimère du disulfure avec la chaîne κ de l’anticorps monoclonal chimérique
                                         homme-souris 2D10

    vapaliximab                          inmunoglobulina G2, anti-(proteína de adhesión vascular humana VAP-1)
                                         (cadena γ2 del anticuerpo monoclonal quimérico hombre-ratón 2D10),
                                         dímero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico
                                         hombre-ratón 2D10




                                                                                                                            139
Recommended INN: List 49                                        WHO Drug Information, Vol. 17, No. 2, 2003




varespladibum
varespladib                [[3-(aminooxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl]oxy]acetic acid

varespladib                acide [[3-(aminooxoacétyl)-1-benzyl-2-éthyl-1H-indol-4-yl]oxy]acétique

varespladib                ácido [[3-(aminooxoacetil)-1-bencil-2-etil-1H-indol-4-il]oxi]acético

                           C21H20N2O5


                                        O      NH2
                             H3C
                                               O
                                    N          O     CO2H




140
3   WHO Drug Information, Vol. 17, No. 2, 2003                                              Recommended INN: List 49




                                AMENDMENTS TO PREVIOUS LISTS
                        MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                            MODIFICACIONES A LAS LISTAS ANTERIORES



    Recommended International Nonproprietary Names (Rec. INN): List 46
    Dénominations communes internationales recommandées (DCI Rec.): Liste 46
    Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 46
    (WHO Drug Information, Vol. 15, No. 3-4, 2001)


    p. 208 reglitazarum
           reglitazar                            sustituyase la descripción por la siguiente:
                                                 (4RS)-4-[4-[2-fenil-5-metiloxazol-4-il)etoxi]bencil]isoxazolidina-
                                                 3,5-diona


    p. 208 rivoglitazonum
           rivoglitazona                         sustituyase la descripción por la siguiente:
                                                 (5RS)-5-[4-[(1-metil-6-metoxi-1H-bencimidazol-
                                                 2-il)metoxi]bencil]tiazolidina-2,4-diona


    p. 217 delete/supprimer/suprimase            insert/insérer/insértese

           tebipenemum                           tebipenemum pivoxilum
           tebipenem                             tebipenem pivoxil
           tébipénem                             tébipénem pivoxil
           tebipenem                             tebipenem pivoxilo




    Recommended International Nonproprietary Names (Rec. INN): List 48
    Dénominations communes internationales recommandées (DCI Rec.): Liste 48
    Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 48
    (WHO Drug Information, Vol. 16, No. 3, 2002)


    p. 255 metelimumabum
           metelimumab                           replace the description by the following:
                                                 immunoglobulin G4, anti-(human transforming growth factor β1)
                                                 (human monoclonal CAT-192 γ4-chain), disulfide with human
                                                 monoclonal CAT-192 κ-chain, dimer




                                                                                                                      141
Recommended INN: List 49                                                    WHO Drug Information, Vol. 17, No. 2, 2003




p. 258 paliferminum
       palifermin                              replace the description and the graphic formula by the following:
                                               human fibroblast growth factor-(24-163)-peptide

       palifermine                             remplacer la description et la formule developpée par la suivante:
                                               peptide-(24-163)-facteur de croissance du fibroblaste humain

       palifermina                             sustitúyase la descripción y la fórmula empírica por la siguiente:
                                               péptido-(24-163)-factor de crecimiento del fibroblasto humano


                                                                                       SYDYMEG        GDIRVRRLFC
                                               RTQWYLRIDK         RGKVKGTQEM        KNNYNIMEIR        TVAVGIVAIK
                                               GVESEFYLAM         NKEGKLYAKK        ECNEDCNFKE        LILENHYNTY
                                               ASAKWTHNGG         EMFVALNQKG        IPVRGKKTKK        EQKTAHFLPM
                                               AIT


p. 267 delete/supprimer/suprimase              insert/insérer/insértese

       pitrakinraum                            pitrakinrum




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in uneven numbers of proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour
les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internatio-
nales applicables aux substances pharmaceutiques seront publiés seulement dans les numéros impaires des listes
des DCIs proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las
sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes
internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.



142
